MX9605355A - El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer. - Google Patents

El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer.

Info

Publication number
MX9605355A
MX9605355A MX9605355A MX9605355A MX9605355A MX 9605355 A MX9605355 A MX 9605355A MX 9605355 A MX9605355 A MX 9605355A MX 9605355 A MX9605355 A MX 9605355A MX 9605355 A MX9605355 A MX 9605355A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
cancer
treatment
small cell
cancer patients
Prior art date
Application number
MX9605355A
Other languages
English (en)
Other versions
MXPA96005355A (es
Inventor
Harry R Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9605355A publication Critical patent/MX9605355A/es
Publication of MXPA96005355A publication Critical patent/MXPA96005355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion se refiere al uso de ciertos antagonistas de receptor NK-1- (por ejemplo antagonistas de receptor de la sustancia P) para tratar a pacientes con cáncer, en particular a pacientes que padecen un carcinoma de pulmon de células pequeñas, APUDoma, astrocitoma, tumor neuroendocrino o carcinoma de células pequeñas extrapulmonar.
MXPA/A/1996/005355A 1995-11-06 1996-11-04 El uso de antagonistas de receptor nk-1 para preparar composiciones para tratar cancer MXPA96005355A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US727595P 1995-11-06 1995-11-06
US007275 1995-11-06
US1023296P 1996-01-19 1996-01-19
US010232 1996-01-19

Publications (2)

Publication Number Publication Date
MX9605355A true MX9605355A (es) 1997-10-31
MXPA96005355A MXPA96005355A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
JPH09124483A (ja) 1997-05-13
KR970027053A (ko) 1997-06-24
AU7059296A (en) 1997-05-15
CA2189501A1 (en) 1997-05-07
EP0773026A2 (en) 1997-05-14
AU700520B2 (en) 1999-01-07
EP0773026A3 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
SI1187632T1 (sl) Zdravljenje z anti-ErbB2 protitelesi
HK1032759A1 (en) Apparatus for restoring the balance of the human body.
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
MX9805255A (es) Antagonistas de receptor de vitronectina.
LU90388B1 (fr) Sel de paroxetine nouveau procede pour sa preparation et compositions pharmaceutiques le contenant
BG102726A (en) Combined therapy for osteoporosis
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
HK1034523A1 (en) Hemiasterlin analogs
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
AU2002217668A1 (en) Activity aid apparatus
EP0773026A3 (en) NK-1 receptor antagonists for the treatment of cancer
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EP1185276A4 (en) ISOPHOSPHORAMIDE MUSTARD GAS ANALOGS AND THEIR USE
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
GB9924941D0 (en) Treatment of dyskinesia
IL139144A0 (en) Mycobacterial inhibitors
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
ZA969285B (en) NK-1 receptor antagonists for the treatment of cancer.